217 related articles for article (PubMed ID: 37344529)
1. Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab.
Valls R; Wagg J; Paz-Priel I; Man G; Artigas L; Jaccard G; Coma M; Schmitt C
Sci Rep; 2023 Jun; 13(1):10078. PubMed ID: 37344529
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
3. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the safety of emicizumab in patients with hemophilia A.
Langer AL; Etra A; Aledort L
Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
[TBL] [Abstract][Full Text] [Related]
5. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
6. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence.
Kenet G; Fujii T
Haemophilia; 2024 Mar; 30(2):267-275. PubMed ID: 38291654
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
Kizilocak H; Marquez-Casas E; Phei Wee C; Malvar J; Carmona R; Young G
Haemophilia; 2021 Jan; 27(1):164-172. PubMed ID: 33245833
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
9. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
[No Abstract] [Full Text] [Related]
10. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Lenting PJ; Denis CV; Christophe OD
Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
[TBL] [Abstract][Full Text] [Related]
11. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
Hartmann R; Feenstra T; Valentino L; Dockal M; Scheiflinger F
J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888855
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of emicizumab for the treatment of hemophilia A.
Yoneyama K; Schmitt C; Portron A; Kiialainen A; Kotani N; Jaminion F; Retout S; Adamkewicz JI
Expert Rev Clin Pharmacol; 2023; 16(9):775-790. PubMed ID: 37529848
[TBL] [Abstract][Full Text] [Related]
13. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
14. Emicizumab for the treatment of haemophilia A: a narrative review.
Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
[TBL] [Abstract][Full Text] [Related]
16. Utilization of emicizumab in acquired hemophilia A: A case report.
Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
[TBL] [Abstract][Full Text] [Related]
17. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.
Atsou S; Schellenberg C; Lagrange J; Lacolley P; Lenting PJ; Denis CV; Christophe OD; Regnault V
J Thromb Haemost; 2024 Jan; 22(1):112-125. PubMed ID: 37776978
[TBL] [Abstract][Full Text] [Related]
18. Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.
Ogiwara K; Taki M; Suzuki T; Takedani H; Matsushita T; Amano K; Matsumoto M; Nishio K; Shima M; Kasahara M; Nogami K
BMJ Open; 2022 Feb; 12(2):e056922. PubMed ID: 35177463
[TBL] [Abstract][Full Text] [Related]
19. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab.
Kizilocak H; Marquez-Casas E; Malvar J; Young G
Haemophilia; 2023 Jan; 29(1):100-105. PubMed ID: 36287631
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel.
Escuriola-Ettingshausen C; Auerswald G; Königs C; Kurnik K; Scholz U; Klamroth R; Oldenburg J
Haemophilia; 2021 May; 27(3):e305-e313. PubMed ID: 32937002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]